CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Overtly healthy native Chinese males or females
  • ✓BMI 18–28 kg/m²
  • ✓Nonsmokers
  • ✓Fasting plasma glucose 71–108 mg/dL (3.9–6.0 mmol/L)
Key exclusion· 7
  • ✕Enrolled in or participated in a clinical study within last 30 days
  • ✕Prior participation in studies of LY900014
  • ✕Known allergies to LY900014 or formulation components
  • ✕Significant history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that could alter drug absorption/metabolism/elimination or interfere with data interpretation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04049123
NCT04049123Phase 1Completed
CompareCT.gov

A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Following Single Dose Administration in Healthy Chinese Subjects

Eli Lilly and Company·interventional·Posted Aug 7, 2019·Updated Nov 16, 2021

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Healthy. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the effect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 7, 2019
Enrollment StartNov 18, 2019
Primary CompletionOct 23, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.9 years ago

Interventions

LY900014drug

Administered SC

Insulin Lisprodrug

Administered SC